See also this year's filing and all EDGAR filings for this company.
PDF Report 0001367644_2021_Emergent_Biosolutions_Inc.pdf
Logs
| warning | Large missing amount for aggregate "Revenues" added to remainder. | industry.us_generic | {'missing_ratio': inf, 'aggregate_val': 1792700000, 'exp_sum': 0, 'exp_to_value': {'remainder_Revenues': 0}} |
| warning | Large missing amount for aggregate "Expenses" added to remainder. | industry.us_generic | {'missing_ratio': 0.9887743114475916, 'aggregate_val': 1523600000, 'exp_sum': 766100000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 348400000, 'ResearchAndDevelopmentExpense': 234000000, 'remainder_Expenses': 183700000}} |
Graph
Absolute values for 0001367644, Emergent Biosolutions Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 1,195,900,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 929,800,000 |
| 2 | PropertyPlantAndEquipmentNet | 644,100,000 |
| 3 | remainder_Assets | 113,400,000 |
| 4 | LiabilitiesCurrent | 384,500,000 |
| 5 | LiabilitiesNoncurrent | 964,300,000 |
| 6 | remainder_Liabilities | 87,400,000 |
| 7 | CostOfGoodsAndServicesSold | 547,868,810 |
| 8 | SellingGeneralAndAdministrativeExpense | 311,365,672 |
| 9 | ResearchAndDevelopmentExpense | 234,726,162 |
| 10 | remainder_Expenses | 135,164,449 |
| 11 | remainder_Revenues | 2,260,585,510 |
| 12 | remainder_NetIncome | -11,620,762 |
| 13 | remainder_ComprehensiveNetIncome | -41,078,245 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 2,883,200,000 |
| 1 | Liabilities | 1,436,200,000 |
| 2 | Expenses | 1,229,125,093 |
| 3 | Revenues | 2,260,585,510 |
| 4 | StockholdersEquity | 1,447,000,000 |
| 5 | NetIncome | 1,019,839,655 |
| 6 | ComprehensiveNetIncome | 999,300,532 |
| 7 | BaseVar | 3,930,904,805 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 1.92 |
| 9 | EconomicCapitalRatio | 2.97 |
Edgar->Model Mapping
Feature Distribution
Change over Time
